BioNTech records loss of 190 mln euros in Q2 as covid vaccine demand wanes

BERLIN, Aug. 7 (Xinhua) -- German developer and manufacturer of active immunotherapies BioNTech on Monday posted a loss of 190 million euros (209 million U.S. dollars) in the second quarter of 2023 as demand for its COVID-19 vaccine waned.

Related Keywords

Berlin ,Germany ,Jens Holstein , ,Chief Financial Officer Jens Holstein ,Ribonucleic Acid ,